Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service

Authors: N. Radhakrishnan, M. Liu, B. Idowu, A. Bansari, K. Rathi, S. Magar, L. Mundhra, J. Sarmiento, U. Ghaffar, J. Kattan, R. Jones, J. George, Y. Yang, F. Southwick

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

While existing evidence suggests less severe clinical manifestations and lower mortality are associated with the Omicron variant as compared to the Delta variant. However, these studies fail to control for differences in health systems facilities and providers. By comparing patients hospitalized on a single medical service during the Delta and Omicron surges we were able to conduct a more accurate comparison of the two varaints’ clinical manifestations and outcomes.

Methods

We conducted a prospective study of 364 Omicron (BA.1) infected patients on a single hospitalist service and compared these findings to a retrospective analysis of 241 Delta variant infected patients managed on the same service. We examined differences in symptoms, laboratory measures, and clinical severity between the two variants and assessed potential risk drivers for case mortality.

Findings

Patients infected with Omicron were older and had more underlying medical conditions increasing their risk of death. Although they were less severely ill and required less supplemental oxygen and dexamethasone, in-hospital mortality was similar to Delta cases, 7.14% vs. 4.98% for Delta (q-value = 0.38). Patients older than 60 years or with immunocompromised conditions had much higher risk of death during hospitalization, with estimated odds ratios of 17.46 (95% CI: 5.05, 110.51) and 2.80 (1.03, 7.08) respectively. Neither vaccine history nor variant type played a significant role in case fatality. The Rothman score, NEWS-2 score, level of neutrophils, level of care, age, and creatinine level at admission were highly predictive of in-hospital death.

Interpretation

In hospitalized patients, the Omicron variant is less virulent than the Delta variant but is associated with a comparable mortality. Clinical and laboratory features at admission are informative about the risk of death.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. J Med Virol 2021. Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. J Med Virol 2021.
2.
go back to reference Madhi SA, Kwatra G, Myers JE et al. Population Immunity and Covid-19 severity with Omicron variant in South Africa. N Engl J Med 2022. Madhi SA, Kwatra G, Myers JE et al. Population Immunity and Covid-19 severity with Omicron variant in South Africa. N Engl J Med 2022.
4.
go back to reference Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with Infection with SARS-CoV-2 Omicron variant versus Delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022;22:967–76.CrossRefPubMedPubMedCentral Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with Infection with SARS-CoV-2 Omicron variant versus Delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022;22:967–76.CrossRefPubMedPubMedCentral
5.
go back to reference Auvigne V, Vaux S, Strat YL, et al. Severe hospital events following symptomatic Infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: a retrospective, population-based, matched cohort study. EClinicalMedicine. 2022;48:101455.CrossRefPubMedPubMedCentral Auvigne V, Vaux S, Strat YL, et al. Severe hospital events following symptomatic Infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: a retrospective, population-based, matched cohort study. EClinicalMedicine. 2022;48:101455.CrossRefPubMedPubMedCentral
6.
go back to reference Sievers C, Zacher B, Ullrich A et al. SARS-CoV-2 omicron variants BA.1 and BA.2 both show similarly reduced Disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill 2022; 27. Sievers C, Zacher B, Ullrich A et al. SARS-CoV-2 omicron variants BA.1 and BA.2 both show similarly reduced Disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Euro Surveill 2022; 27.
7.
go back to reference Kahn F, Bonander C, Moghaddassi M et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill 2022; 27. Kahn F, Bonander C, Moghaddassi M et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill 2022; 27.
8.
go back to reference Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303–12.CrossRefPubMedPubMedCentral Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303–12.CrossRefPubMedPubMedCentral
9.
go back to reference Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C, Collaborators EI. Severity of Omicron variant of concern and effectiveness of vaccine boosters against symptomatic Disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis; 2022. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C, Collaborators EI. Severity of Omicron variant of concern and effectiveness of vaccine boosters against symptomatic Disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis; 2022.
10.
go back to reference Krutikov M, Stirrup O, Nacer-Laidi H, et al. Outcomes of SARS-CoV-2 Omicron Infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. Lancet Healthy Longev. 2022;3:e347–e55.CrossRefPubMedPubMedCentral Krutikov M, Stirrup O, Nacer-Laidi H, et al. Outcomes of SARS-CoV-2 Omicron Infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study. Lancet Healthy Longev. 2022;3:e347–e55.CrossRefPubMedPubMedCentral
11.
go back to reference Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from Omicron, Delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.CrossRefPubMed Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from Omicron, Delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.CrossRefPubMed
12.
go back to reference Paredes MI, Lunn SM, Famulare M, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. Clin Infect Dis; 2022. Paredes MI, Lunn SM, Famulare M, et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. Clin Infect Dis; 2022.
13.
go back to reference Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant Infection in southern California. Nat Med 2022. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant Infection in southern California. Nat Med 2022.
14.
go back to reference Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 Infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12:100297.PubMedPubMedCentral Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 Infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12:100297.PubMedPubMedCentral
15.
go back to reference Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46.CrossRefPubMedPubMedCentral Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46.CrossRefPubMedPubMedCentral
16.
go back to reference Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. JAMA. 2022;327:583–4.CrossRefPubMed Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. JAMA. 2022;327:583–4.CrossRefPubMed
17.
go back to reference Shaheen N, Mohamed A, Attalla A, et al. Could the New BA.2.75 Sub-variant cause the emergence of a global epidemic of COVID-19? A scoping review. Infect Drug Resist. 2022;15:6317–30.CrossRefPubMedPubMedCentral Shaheen N, Mohamed A, Attalla A, et al. Could the New BA.2.75 Sub-variant cause the emergence of a global epidemic of COVID-19? A scoping review. Infect Drug Resist. 2022;15:6317–30.CrossRefPubMedPubMedCentral
18.
go back to reference Engebretsen S, Bogstrand ST, Jacobsen D, Vitelli V, Rimstad R. NEWS2 versus a single-parameter system to identify critically ill medical patients in the emergency department. Resusc Plus. 2020;3:100020.CrossRefPubMedPubMedCentral Engebretsen S, Bogstrand ST, Jacobsen D, Vitelli V, Rimstad R. NEWS2 versus a single-parameter system to identify critically ill medical patients in the emergency department. Resusc Plus. 2020;3:100020.CrossRefPubMedPubMedCentral
19.
go back to reference Alarhayem AQ, Muir MT, Jenkins DJ, et al. Application of electronic medical record-derived analytics in critical care: Rothman Index predicts mortality and readmissions in surgical intensive care unit patients. J Trauma Acute Care Surg. 2019;86:635–41.CrossRefPubMed Alarhayem AQ, Muir MT, Jenkins DJ, et al. Application of electronic medical record-derived analytics in critical care: Rothman Index predicts mortality and readmissions in surgical intensive care unit patients. J Trauma Acute Care Surg. 2019;86:635–41.CrossRefPubMed
20.
go back to reference Chan AS, Rout A, Adamo CRD, Lev I, Yu A, Miller K. Palliative referrals in Advanced Cancer patients: utilizing the supportive and Palliative Care indicators Tool and Rothman Index. Am J Hosp Palliat Care. 2022;39:164–8.CrossRefPubMed Chan AS, Rout A, Adamo CRD, Lev I, Yu A, Miller K. Palliative referrals in Advanced Cancer patients: utilizing the supportive and Palliative Care indicators Tool and Rothman Index. Am J Hosp Palliat Care. 2022;39:164–8.CrossRefPubMed
21.
go back to reference Lambrou AS, Shirk P, Steele MK, et al. Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants - United States, June 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:206–11.CrossRefPubMedPubMedCentral Lambrou AS, Shirk P, Steele MK, et al. Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants - United States, June 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:206–11.CrossRefPubMedPubMedCentral
22.
go back to reference Armando F, Beythien G, Kaiser FK, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. Nat Commun. 2022;13:3519.CrossRefPubMedPubMedCentral Armando F, Beythien G, Kaiser FK, et al. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. Nat Commun. 2022;13:3519.CrossRefPubMedPubMedCentral
23.
go back to reference Mohandas S, Yadav PD, Sapkal G, et al. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. EBioMedicine. 2022;79:103997.CrossRefPubMedPubMedCentral Mohandas S, Yadav PD, Sapkal G, et al. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. EBioMedicine. 2022;79:103997.CrossRefPubMedPubMedCentral
24.
go back to reference Natekar JP, Pathak H, Stone S et al. Differential Pathogenesis of SARS-CoV-2 variants of concern in human ACE2-Expressing mice. Viruses 2022; 14. Natekar JP, Pathak H, Stone S et al. Differential Pathogenesis of SARS-CoV-2 variants of concern in human ACE2-Expressing mice. Viruses 2022; 14.
25.
go back to reference Tarres-Freixas F, Trinite B, Pons-Grifols A, et al. Heterogeneous infectivity and Pathogenesis of SARS-CoV-2 variants Beta, Delta and Omicron in Transgenic K18-hACE2 and wildtype mice. Front Microbiol. 2022;13:840757.CrossRefPubMedPubMedCentral Tarres-Freixas F, Trinite B, Pons-Grifols A, et al. Heterogeneous infectivity and Pathogenesis of SARS-CoV-2 variants Beta, Delta and Omicron in Transgenic K18-hACE2 and wildtype mice. Front Microbiol. 2022;13:840757.CrossRefPubMedPubMedCentral
26.
go back to reference Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med. 2022;386:e14.CrossRefPubMed Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N Engl J Med. 2022;386:e14.CrossRefPubMed
27.
go back to reference Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the Omicron wave in South Africa: a retrospective observational study. Lancet Glob Health; 2022. Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the Omicron wave in South Africa: a retrospective observational study. Lancet Glob Health; 2022.
28.
go back to reference Davies MA, Kassanjee R, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 Infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health. 2022;27:564–73.CrossRefPubMedPubMedCentral Davies MA, Kassanjee R, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 Infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health. 2022;27:564–73.CrossRefPubMedPubMedCentral
29.
go back to reference Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 Infection during periods of B.1.617.2 (Delta) and B.1.1.529 (omicron) variant predominance - one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–23.CrossRefPubMedPubMedCentral Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 Infection during periods of B.1.617.2 (Delta) and B.1.1.529 (omicron) variant predominance - one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–23.CrossRefPubMedPubMedCentral
30.
go back to reference Adhikari EH, MacDonald L, SoRelle JA, Morse J, Pruszynski J, Spong CY. COVID-19 cases and Disease severity in pregnancy and neonatal positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) variant predominance. JAMA. 2022;327:1500–2.CrossRefPubMedPubMedCentral Adhikari EH, MacDonald L, SoRelle JA, Morse J, Pruszynski J, Spong CY. COVID-19 cases and Disease severity in pregnancy and neonatal positivity Associated With Delta (B.1.617.2) and Omicron (B.1.1.529) variant predominance. JAMA. 2022;327:1500–2.CrossRefPubMedPubMedCentral
31.
go back to reference Ozdalga E, Ahuja N, Sehgal N et al. Detailed characterization of hospitalized patients infected with the Omicron variant of SARS-CoV-2. J Intern Med 2022. Ozdalga E, Ahuja N, Sehgal N et al. Detailed characterization of hospitalized patients infected with the Omicron variant of SARS-CoV-2. J Intern Med 2022.
32.
go back to reference Stalcrantz J, Kristoffersen AB, Boas H et al. Milder Disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway. Scand J Public Health 2022:14034948221108548. Stalcrantz J, Kristoffersen AB, Boas H et al. Milder Disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway. Scand J Public Health 2022:14034948221108548.
33.
go back to reference Van Goethem N, Chung PYJ, Meurisse M et al. Clinical severity of SARS-CoV-2 omicron variant compared with Delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021–2022. Viruses 2022; 14. Van Goethem N, Chung PYJ, Meurisse M et al. Clinical severity of SARS-CoV-2 omicron variant compared with Delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021–2022. Viruses 2022; 14.
34.
35.
go back to reference Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infect Dis. 2022;22:816.CrossRefPubMedPubMedCentral Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infect Dis. 2022;22:816.CrossRefPubMedPubMedCentral
36.
go back to reference Veldhuis L, Ridderikhof ML, Schinkel M, et al. Early warning scores to assess the probability of critical Illness in patients with COVID-19. Emerg Med J. 2021;38:901–5.CrossRefPubMed Veldhuis L, Ridderikhof ML, Schinkel M, et al. Early warning scores to assess the probability of critical Illness in patients with COVID-19. Emerg Med J. 2021;38:901–5.CrossRefPubMed
37.
go back to reference Moguillansky D, Sharaf OM, Jin P, et al. Evaluation of clinical predictors for major outcomes in patients hospitalized with COVID-19: the potential role of the Rothman Index. Cureus. 2022;14:e28769.PubMedPubMedCentral Moguillansky D, Sharaf OM, Jin P, et al. Evaluation of clinical predictors for major outcomes in patients hospitalized with COVID-19: the potential role of the Rothman Index. Cureus. 2022;14:e28769.PubMedPubMedCentral
38.
go back to reference Beals Jt, Barnes JJ, Durand DJ, et al. Stratifying deterioration risk by acuity at admission offers triage insights for Coronavirus Disease 2019 patients. Crit Care Explor. 2021;3:e0400.CrossRef Beals Jt, Barnes JJ, Durand DJ, et al. Stratifying deterioration risk by acuity at admission offers triage insights for Coronavirus Disease 2019 patients. Crit Care Explor. 2021;3:e0400.CrossRef
Metadata
Title
Comparison of the clinical characteristics of SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) infected patients from a single hospitalist service
Authors
N. Radhakrishnan
M. Liu
B. Idowu
A. Bansari
K. Rathi
S. Magar
L. Mundhra
J. Sarmiento
U. Ghaffar
J. Kattan
R. Jones
J. George
Y. Yang
F. Southwick
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08714-x

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine